cordycepin (OVI-123)

Our results suggested that 8 biomarkers including SLC2A1, SMS, CCNA2, CDC25C, RNASE1, NR3C2, CAT, and ADA were associated with PANoptosis in LUAD. These findings may provide supportive evidence for the prognosis prediction and treatment of LUAD. However, the involvement of these genes in PANoptosis is currently only a hypothesis based on bioinformatics analysis and requires further experimental validation in the future.

Molecular docking and dynamics simulations were performed to validate the interactions of CME's potent bioactive compound, cordycepin with anti-apoptotic target proteins, BCL-2, BCL-xL and BFL-1...CME induces mitochondria-mediated apoptosis, DNA damage and cell cycle arrest in DL cells. This highlights the potential of C. militaris as a natural anticancer drug against lymphoma, thereby warranting further clinical validation for phytotherapeutic applications.

Ophiocordyceps sinensis demonstrates encouraging anticancer potential in preclinical models. Further clinical studies are essential to validate its efficacy, establish safety profiles, and optimize formulation for therapeutic use.

This review summarizes the anti-inflammatory effects of cordycepin on oxidative stress. These findings indicate that cordycepin exerts favorable anti-inflammatory effects during inflammatory responses.

Importantly, CME caused no systemic toxicity, and its approximate lethal dose was over 5000 mg/kg. Together, these findings suggest CME as a potent ferroptosis-inducing agent against lung cancer and establish C. militaris as a promising candidate for redox-targeted cancer therapy.

The combination treatment (CC) largely reflected Cu-driven morphological and functional changes, with Co coexisting without counteracting Cu's effects. Taken together, these findings reveal compound-specific mechanisms of action for Cu and Co in OSCC therapy.

In fed-batch fermentation, SCC7 achieved 6972.8 mg/L COR in a 6 L bioreactor, representing the highest COR titer reported in S. cerevisiae to date. In conclusion, this study establishes an efficient yeast platform for COR production and provides a useful reference for biosynthesis of other bioactive nucleosides.

Given its oncogenic potential, this study aimed to investigate the potential of SOX2 as a biomarker and evaluate the inhibitory effects of cordycepin (CD), a natural compound, on SOX2-driven oncogenic phenotypes in lung cancer...Moreover, overexpression of SOX2 promoted lung cancer cell growth, migration, and invasion, while CD, a natural product originally from the traditional Chinese medicine Cordyceps sinensis (BerK.), suppressed SOX2-mediated progression, including the growth, migration, and invasion of lung cancer. Taken together, these results implied that SOX2 is a potential biomarker for diagnostics, prognostics, and therapeutics for lung cancer, including LUAD and LUSC.

The review lists over 18 mushroom species (e.g., Ganoderma lucidum, Cordyceps, Phellinus) and 28 bioactive compounds (such as Ganoderic acid DM, Cordycepin, Hispidin) that affect autophagy, demonstrating efficacy against 15 cancer types, including colorectal, lung, breast, and liver cancers...The context-dependent effects of autophagy, along with the limited clinical evidence, present considerable challenges. Future clinical trials must focus on developing standardized extracts and personalized approaches to effectively translate this potential into clinical practice.

Mice exhibiting PTSD-like behaviour were treated with fluoxetine (FLU, 10 mg/kg), an antidepressant drug, and COR (10 and 50 mg/kg). COR demonstrated a dose-dependent response with 50 mg/kg showing consistent improvement in both behavioural and biochemical parameters. Overall, COR exhibited promising activity in this model and may serve as a potential natural therapeutic strategy to investigate for the management of PTSD in clinics.

Non-targeted metabolomics analysis using LC-MS identified specific activation of the histidine metabolism pathway, with elevated levels of the key metabolite Cetirizine N-Oxide potentially contributing to enhanced immune activity. Mechanistic studies further revealed that the triple therapy suppresses the activity of the Bcl6 regulatory network, thereby reducing the immunosuppressive function of Tregs and destroying the immunosuppressive interplay between myeloid immune cells and Tregs. These results demonstrate a promising "microbiome-immune" dual-targeting strategy for colon cancer with clinical translational potential.

Functionally, COR treatment inhibited EVT cell invasion, and this effect was mediated by MMP2 downregulation. These findings provide new insights into the molecular mechanisms by which COR regulates EVT cell invasiveness and highlight the potential implications of COR as a health supplement during pregnancy.